Iron (Fe) sequestration is described in overweight and in its associated metabolic complications, i.e., metabolic syndrome (MetS) and non-alcoholic liver fatty disease (NAFLD); however, the interactions between Fe, obesity and inflammation make it difficult to recognize the specific role of each of them in the risk of obesity-induced metabolic diseases. Even the usual surrogate marker of Fe stores, ferritin, is influenced by inflammation; therefore, in obese subjects inflammation parameters must be measured together with those of Fe metabolism. This cross-sectional study in obese youth (502 patients; 57% girls): 11.4 ± 3.0 years old (x ± SD); BMI z score 5.5 ± 2.3), multivariate regression analysis showed associations between Fe storage assessed by serum ferritin with risk factors for MetS and NAFLD, assessed by transaminase levels, which were independent of overweight and the acute phase protein fibrinogen. Further studies incorporating the measurement of complementary parameters of Fe metabolism could improve the comprehension of mechanisms involved.
References
[1]
Pinhas-Hamiel, O.; Newfield, R.S.; Koren, I.; Agmon, A.; Lilos, P.; Phillip, M. Greater prevalence of iron deficiency in overweight and obese children and adolescents. Int. J. Obes. Relat. Metab. Disord. 2003, 27, 416–418, doi:10.1038/sj.ijo.0802224.
[2]
Nead, K.G.; Halterman, J.S.; Kaczorowski, J.M.; Auinger, P.; Weitzman, M. Overweight children and adolescents: A risk group for iron deficiency. Pediatrics 2004, 114, 104–108, doi:10.1542/peds.114.1.104.
[3]
Mandato, C.; Lucariello, S.; Licenziati, M.R.; Franzese, A.; Spagnuolo, M.I.; Ficarella, R.; Pacilio, M.; Amitrano, M.; Capuano, G.; Meli, R.; et al. Metabolic, hormonal, oxidative, and inflammatory factors in pediatric obesity-related liver disease. J. Pediatr. 2005, 147, 62–66, doi:10.1016/j.jpeds.2005.02.028.
[4]
Moayeri, H.; Bidad, K.; Zadhoush, S.; Gholami, N.; Anari, S. Increasing prevalence of iron deficiency in overweight and obese children and adolescents (Tehran Adolescent Obesity Study). Eur. J. Pediatr. 2006, 165, 813–814, doi:10.1007/s00431-006-0178-0.
[5]
Brotanek, J.M.; Gosz, J.; Weitzman, M.; Flores, G. Iron deficiency in early childhood in the United States: Risk factors and racial/ethnic disparities. Pediatrics 2007, 120, 569–575.
[6]
Richardson, M.W.; Ang, L.; Visintainer, P.F.; Wittcopp, C.A. The abnormal measures of iron homeostasis in pediatric obesity are associated with the inflammation of obesity. Int. J. Pediatr. Endocrinol. 2009, 713269, doi:10.1155.2009/713269.
[7]
Amato, A.; Santoro, N.; Calabrò, P.; Grandone, A.; Swinkels, D.W.; Perrone, L.; Miraglia del Giudice, E. Effect of body mass index reduction on serum hepcidin levels and iron status in obese children. Int. J. Obes. 2010, 34, 1772–1774, doi:10.1038/ijo.2010.204.
[8]
Cheng, H.L.; Bryant, C.; Cookn, R.; O’Connor, H.; Rooneyn, K.; Steinbeck, K. The relationship between obesity and hypoferraemia in adults: A systematic review. Obes. Rev. 2012, 3, 150–161.
[9]
Moschonis, G.; Chrousos, G.P.; Lionis, C.; Mougios, V.; Manios, Y.; Healthy Growth Study Group. Association of total body and visceral fat mass with iron deficiency in preadolescents: The Healthy Growth Study. Br. J. Nutr. 2012, 108, 710–719.
[10]
Baumgartner, J.; Smuts, C.M.; Aeberli, I.; Malan, L.; Tjalsma, H.; Zimmermann, M.B. Overweight impairs efficacy of iron supplementation in iron-deficient South African children: A randomized controlled intervention. Int. J. Obes. 2013, 37, 24–30, doi:10.1038/ijo.2012.145.
[11]
Jehn, M.; Clark, J.M.; Guallar, E. Serum ferritin and risk of the metabolic syndrome in U.S. adults. Diabetes Care 2004, 27, 2422–2428, doi:10.2337/diacare.27.10.2422.
[12]
Choi, K.M.; Lee, K.W.; Kim, H.Y.; Seo, J.A.; Kim, S.G.; Kim, N.H.; Choi, D.S.; Baik, S.H. Association among serum ferritin, alanine aminotransferase levels, and metabolic syndrome in Korean postmenopausal women. Metabolism 2005, 54, 1510–1514, doi:10.1016/j.metabol.2005.05.018.
[13]
Neuschwander-Tetri, B.A. Fatty liver and the metabolic syndrome. Curr. Opin. Gastroenterol. 2007, 23, 193–198, doi:10.1097/MOG.0b013e32801421a9.
[14]
Ahmed, U.; Latham, P.S.; Oates, P.S. Interactions between hepatic iron and lipid metabolism with possible relevance to steatohepatitis. World J. Gastroenterol. 2012, 18, 4651–4658, doi:10.3748/wjg.v18.i34.4651.
[15]
Anses. Choix des Examens du Métabolisme du fer en cas de Suspicion de Carence en fer––Rapport D’évaluation Technologique (in French), Available online: http://www.has-sante.fr/portail/jcms/c_1051506/choix-des-examens-du-metabolisme-du-fer-en-cas-de-suspicion-de-carence-en-fer-rapport-d-evaluation (accessed on 20 March 2013).
[16]
World Health Organization. Iron Deficiency Anaemia—Assessment, Prevention and Control; WHO: Geneva, Switzerland, 2001.
[17]
Tussing-Humphreys, L.; Pusatcioglu, C.; Nemeth, E.; Braunschweig, C. Rethinking iron regulation and assessment in iron deficiency, anemia of chronic disease, and obesity: Introducing hepcidin. J. Acad. Nutr. Diet. 2012, 112, 391–400, doi:10.1016/j.jada.2011.08.038.
[18]
Brugnara, C. Iron deficiency: What are the future trends in diagnostics and therapeutics? Clin. Chem. 2013, 59, 740–745, doi:10.1373/clinchem.2012.182071.
[19]
Engle-Stone, R.; Nankap, M.; Ndjebayi, A.O.; Erhardt, J.G.; Brown, K.H. Plasma ferritin and soluble transferrin receptor concentrations and body iron stores identify similar risk factors for irondeficiency but result in different estimates of the national prevalence of irondeficiency and iron-deficiency anemia among women and children in Cameroon. J. Nutr. 2013, 143, 369–377, doi:10.3945/jn.112.167775.
[20]
Rolland-Cachera, M.F.; Cole, T.J.; Sempé, M.; Tichet, J.; Rossignol, C.; Charraud, A. Body Mass Index variations: Centiles from birth to 87 years. Eur. J. Clin. Nutr. 1991, 45, 13–21.
[21]
Hercberg, S.; Preziosi, P.; Galan, P. Iron deficiency in Europe. Public Health Nutr. 2001, 4, 537–745.
[22]
Cooper, M.; Greene-Finestone, L.; Lowell, H.; Levesque, J.; Robinson, S. Iron sufficiency of Canadians. Health Rep. 2012, 23, 3–10.
[23]
Whaley-Connell, A.; McCullough, P.A.; Sowers, J.R. The role of oxidative stress in the metabolic syndrome. Rev. Cardiovasc. Med. 2011, 12, 21–29.
[24]
Fumeron, F.; Pean, F.; Driss, F.; Balkau, B.; Tichet, J.; Marre, M.; Grandchamp, B. Ferritin and transferrin are both predictive of the onset of hyperglycemia in men and women over 3 years: The data from an epidemiological study on the Insulin Resistance Syndrome (DESIR) study. Diabetes Care 2006, 29, 2090–2094, doi:10.2337/dc06-0093.
[25]
Wrede, C.E.; Buettner, R.; Bollheimer, L.C.; Scholmerich, J.; Palitzsch, K.D.; Hellerbrand, C. Association between serum ferritin and the insulin resistance syndrome in a representative population. Eur. J. Endocrinol. 2006, 154, 333–340, doi:10.1530/eje.1.02083.
[26]
Dongiovanni, P.; Fracanzani, A.L.; Fargion, S.; Valenti, L. Iron in fatty liver and in the metabolic syndrome: A promising therapeutic target. J. Hepatol. 2011, 55, 1120–1124.
[27]
Valenti, L.; Swinkels, D.W.; Burdick, L.; Dongiovannin, P.; Tjalsman, H.; Mottan, B.M.; Bertelli, C.; Fatta, E.; Bignamini, D.; Rametta, R. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 568–575, doi:10.1016/j.numecd.2010.01.003.
[28]
Harrison-Findik, D.D. Gender-related variations in iron metabolism and liver diseases. World J. Hepatol. 2010, 2, 302–310, doi:10.4254/wjh.v2.i8.302.
[29]
Fernandez-Real, J.M.; Lopez-Bermejo, A.; Ricart, W. Iron stores, blood donation, and insulin sensitivity and secretion. Clin. Chem. 2005, 51, 1201–1205, doi:10.1373/clinchem.2004.046847.
[30]
Gonzalez, A.S.; Guerrero, D.B.; Soto, M.B.; Diaz, S.P.; Martinez-Olmos, M.; Vidal, O. Metabolic syndrome, insulin resistance and the inflammation markers C-reactive protein and ferritin. Eur. J. Clin. Nutr. 2006, 60, 802–809, doi:10.1038/sj.ejcn.1602384.
[31]
Zelber-Sagi, S.; Nitzan-Kaluski, D.; Halpern, Z. NAFLD and hyperinsulinemia are major determinants of serum ferritin levels. J. Hepatol. 2007, 46, 700–707, doi:10.1016/j.jhep.2006.09.018.
[32]
Lecube, A.; Hernández, C.; Pelegrí, D.; Simó, R. Factors accounting for high ferritin levels in obesity. Int. J. Obes. (Lond.) 2008, 32, 1665–1669.
[33]
Sun, L.; Franco, O.H.; Hu, F.B.; Cai, L.; Yu, Z.; Li, H.; Ye, X.; Qi, Q.; Wang, J.; Pan, A.; et al. Ferritin concentrations, metabolic syndrome, and type 2 diabetes in middle-aged and elderly chinese. J. Clin. Endocrinol. Metab. 2008, 93, 4690–4696, doi:10.1210/jc.2008-1159.
[34]
Dubern, B.; Girardet, J.P.; Tounian, P. Insulin resistance and ferritin as major determinants of abnormal serum aminotransferase in severely obese children. Int. J. Pediatr. Obes. 2006, 1, 77–82, doi:10.1080/17477160600569594.
[35]
Ford, E.S.; Ajani, U.A.; Mokdad, A.H. The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care 2005, 28, 878–881, doi:10.2337/diacare.28.4.878.
[36]
Skinner, A.C.; Steiner, M.J.; Henderson, F.W.; Perrin, E.M. Multiple markers of inflammation and weight status: Cross-sectional analyses throughout childhood. Pediatrics 2010, 125, e801–e809, doi:10.1542/peds.2009-2182.
[37]
Syrovatka, P.; Kraml, P.; Potockova, J.; Fialova, L.; Vejrazka, M.; Crkovska, J.; Andel, M. Relationship between increased body iron stores, oxidative stress and insulin resistance in healthy men. Ann. Nutr. Metab. 2009, 54, 268–274, doi:10.1159/000229507.
[38]
Tussing-Humphreys, L.M.; Liang, H.; Nemeth, E.; Freels, S.; Braunschweig, C.A. Excess adiposity, inflammation, and iron-deficiency in female adolescents. J. Am. Diet. Assoc. 2009, 109, 297–302, doi:10.1016/j.jada.2008.10.044.
[39]
Cepeda-Lopez, A.C.; Osendarp, S.J.; Melse-Boonstra, A.; Aeberli, I.; Gonzalez-Salazar, F.; Feskens, E.; Villalpando, S.; Zimmermann, M.B. Sharply higher rates of iron deficiency in obese Mexican women and children are predicted by obesity-related inflammation rather than by differences in dietary iron intake. Am. J. Clin. Nutr. 2011, 93, 975–983, doi:10.3945/ajcn.110.005439.
[40]
Hiura, M.; Kikuchi, T.; Nagasaki, K.; Uchiyama, M. Elevation of serum C-reactive protein levels is associated with obesity in boys. Hypertens. Res. 2003, 26, 541–546, doi:10.1291/hypres.26.541.
[41]
Houschyar, K.S.; Lüdtke, R.; Dobos, G.J.; Kalusn, U.; Broecker-Preussn, M.; Rampp, T.; Brinkhaus, B.; Michalsen, A. Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: Results from a randomized clinical trial. BMC Med. 2012, 10, 54, doi:10.1186/1741-7015-10-54.
[42]
Sumida, Y.; Kanemasa, K.; Fukumoto, K.; Yoshida, N.; Sakai, K.; Nakashima, T.; Okanoue, T. Effect of iron reduction by phlebotomy in Japanese patients with nonalcoholic steatohepatitis: A pilot study. Hepatol. Res. 2006, 36, 315–321, doi:10.1016/j.hepres.2006.08.003.
[43]
Escobar-Morreale, H.F.; Villuendas, G.; Botella-Carretero, J.I.; Sancho, J.; San Millan, J.L. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003, 46, 625–633.
[44]
Kowdley, K.V.; Belt, P.; Wilson, L.A.; Yeh, M.M.; Neuschwander-Tetri, B.A.; Chalasani, N. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55, 77–85, doi:10.1002/hep.24706.
[45]
Aigner, E.; Theurl, I.; Theurl, M.; Lederer, D.; Haufe, H.; Dietze, O.; Strasser, M.; Datz, C.; Weiss, G. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 2008, 87, 1374–1383.
[46]
Gabrielsen, J.; Gao, Y.; Simcox, J.A.; Huang, J.; Thorup, D.; Jones, D.; Cooksey, R.C.; Gabrielsen, D.; Adams, T.D.; Hunt, S.C.; et al. Adipocyte iron regulates adiponectin and insulin sensitivity. J. Clin. Investig. 2012, 122, 3529–3540, doi:10.1172/JCI44421.
[47]
Datz, C.; Felder, T.K.; Niederseer, D.; Aigner, E. Iron homeostasis in the Metabolic Syndrome. Eur. J. Clin. Investig. 2013, 43, 215–224, doi:10.1111/eci.12032.
